Kiniksa Pharmaceuticals Ltd. Class A (KNSA)

Name: Kiniksa Pharmaceuticals Ltd. Class A (KNSA) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Kiniksa Pharmaceuticals Ltd. Class A (KNSA)

Stock Card

$79.47

$-0.34 (-0.42%)

As on 28-Aug-2026 11:38EDT

Market cap

$6,166 Mln

Revenue (TTM)

$841 Mln

P/E Ratio

79.8

P/B Ratio

9.4

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Kiniksa Pharmaceuticals Ltd. Class A (KNSA) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 77.98 High: 79.81

52 Week Range

Low: 33.25 High: 82.94

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

0.1 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

55.3
Debt to Equity

0
Book Value

$--
EPS

$1
Face value

--
Shares outstanding

48,289,273

8 Years Aggregate

CFO

$-555.19 Mln

EBITDA

$-687.67 Mln

Net Profit

$-475.80 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Kiniksa Pharmaceuticals Ltd. Class A (KNSA)	92.6	25.1	53.3	135.8	65.8	44.1	--
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021	2020	2019
Kiniksa Pharmaceuticals Ltd. Class A (KNSA)	108.5	17.1	27.3	-33.4	59.8	-60.6
S&P Small-Cap 600	4.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Kiniksa Pharmaceuticals Ltd. Class A (KNSA)

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta... cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom. Read more

CEO & Chairman of the Board

Mr. Sanj K. Patel
CEO & Chairman of the Board

Mr. Sanj K. Patel
Headquarters

London
Website

https://www.kiniksa.com

FAQs for Kiniksa Pharmaceuticals Ltd. Class A (KNSA)

What is the current share price of Kiniksa Pharmaceuticals Ltd Class A (KNSA) Today?

The share price of Kiniksa Pharmaceuticals Ltd Class A (KNSA) is $79.47 (NASDAQ) as of 28-Aug-2026 11:38 EDT. Kiniksa Pharmaceuticals Ltd Class A (KNSA) has given a return of 65.75% in the last 3 years.

What is the current PB & PE ratio of Kiniksa Pharmaceuticals Ltd Class A (KNSA)?

The P/E ratio of Kiniksa Pharmaceuticals Ltd Class A (KNSA) is 79.83 times as on 21-Aug-2026.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	55.21	5.74
2024	-33.12	3.26
2023	90.49	2.90
2022	5.83	2.70
2021	-5.14	4.39

What is the 52 Week High and Low of Kiniksa Pharmaceuticals Ltd Class A (KNSA)?

The 52-week high and low of Kiniksa Pharmaceuticals Ltd Class A (KNSA) are Rs 82.94 and Rs 33.25 as of 28-Aug-2026.

What is the market cap of Kiniksa Pharmaceuticals Ltd Class A (KNSA)?

Kiniksa Pharmaceuticals Ltd Class A (KNSA) has a market capitalisation of $ 6,166 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Kiniksa Pharmaceuticals Ltd Class A (KNSA)?

Before investing in Kiniksa Pharmaceuticals Ltd Class A (KNSA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.